ArticleAmerican journal of translational research2016
Effects of 1,25(OH)2D3 on proliferation and apoptosis of human glomerular mesangial cells.
Article in American journal of translational research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 11 citations in OpenAlex.
- 1.25(OH)2D3 decreases PCNA and mTOR expression and alleviates renal injury in Thy-1 nephritis rat model.PloS one · 2024Article
- Qiteng Xiaozhuo granules medicated serum inhibits excessive proliferation and promotes apoptosis of human glomerular mesangial cells by targeting fat mass and obesity associated proteins.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023Article
- 1α,25(OH)International journal of molecular sciences · 2023Article
- Vitamin D and Glomerulonephritis.Medicina (Kaunas, Lithuania) · 2021Review
- Anticancer activity of 1,25-(OH)OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] on cell proliferation and apoptosis of human glomerular mesangial cells.
methodsHuman glomerular mesangial cells were cultured for 48 h and randomly divided into four groups, normal control group (N group), proliferation group (EGF group ), vitamin D3 intervention group (VD3 group), proliferation intervention group (EGF+VD3 group ). Flow cytometry was used to detect the cell cycle and apoptosis rate, and Western blot was used to detect the PCNA and Caspases-3 expression. The effect of 1,25(OH)2D3 on human mesangial cell proliferation was detected by CCK-8.
resultsCompared with the control group, G1 phase cells in EGF group were significantly reduced, S, G2/M phase cells were increased, and the higher PI and PCNA expression levels were increased; G1 phase cells in VD3 group were increased, S, G2/M phase cells were decreased, and the lower PI and PCNA expression levels were reduced. Compared with EGF group, G1 phase cells in EGF+VD3 group were increased, S, G2/M phase cells were decreased, and the lower PI and PCNA expression levels were significantly reduced. Compared with normal control group, the apoptosis rate in EGF group was significantly lower, and the Caspase-3 expression level was reduced; the apoptosis rate in VD3 group was significantly higher, and Caspase-3 expression was significantly increased. Compared with EGF group, the apoptotic rate of mesangial cells in EGF+VD3 group was significantly increased, and the Caspase-3 expression level was increased, with significant difference.
conclusion1,25(OH)2D3 inhibited the proliferation of mesangial cells and induced their apoptosis by blocking the cell cycle, inhibiting expression of PCNA, and upregulating Caspase-3 expression.
Indexed as
Identifiers
27398149PMC4931160W2514318402What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.